You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Anti-TNF drugs
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Last revisionBoth sides next revision
home:othertreatments:antitnf [08.29.2012] – [Anti-TNF drugs] paulalberthome:othertreatments:antitnf [08.26.2017] – [Increased risk of infection] sallieq
Line 49: Line 49:
  
  
-[[http://www.fda.gov/medwatch/SAFETY/2001/remicadeTB_deardoc.pdf|According to Centocor]], the company which manufactures Remicade, patients taking the drug put themselves at increased risk for opportunistic infection.+[[https://google2.fda.gov/search?q=cache:8wrRnr956OEJ:www.accessdata.fda.gov/drugsatfda_docs/label/2002/inflcen062802lb.pdf+TNF-blocking+agents&client=FDAgov&output=xml_no_dtd&proxystylesheet=FDAgov&site=FDAgov&ie=UTF-8&access=p&oe=UTF-8|According to Centocor]], the company which manufactures Remicade, patients taking the drug put themselves at increased risk for opportunistic infection.
  
 <blockquote>Serious infections, including sepsis and pneumonia, have been reported in patients receiving TNF-blocking agents. Some of these infections have been fatal. <blockquote>Serious infections, including sepsis and pneumonia, have been reported in patients receiving TNF-blocking agents. Some of these infections have been fatal.
  
-//**U.S. Food and Drug Administration**//, [[http://www.fda.gov/MedWatch/safety/2006/Oct_PIs/Remicade_PI.pdf|2006 statement]]</blockquote>+//**U.S. Food and Drug Administration**//, [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/inflcen111099lb.pdf|page 6 : Warnings]]</blockquote>
  
 //M. tuberculosis// is one such infection.(({{pubmed>long:19565495}})) //M. tuberculosis// is one such infection.(({{pubmed>long:19565495}}))
Line 63: Line 63:
 To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}})) To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}}))
  
-"Exaggerated //Borreliosis// infections" have been noted(({{pubmed>long:20184613}})) as have been fatal fungal infections. In 2008, the FDA [[http://www.fda.gov/CDER/drug/InfoSheets/HCP/TNF_blockersHCP.htm|ordered stronger warnings]] on Enbrel, Remicade, Humira and Cimzia due to increased risk of fungal infections.+"Exaggerated //Borreliosis// infections" have been noted(({{pubmed>long:20184613}})) as have been fatal fungal infections. In 2008, the FDA ordered stronger warnings on Enbrel, Remicade, Humira and Cimzia due to increased risk of fungal infections.
  
 Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus.
home/othertreatments/antitnf.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.